# Simplify 2 (NCT02101268)

> Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02101268
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Sierra Oncology LLC - a GSK company
- Conditions: Primary Myelofibrosis (PMF); Post-polycythemia Vera (Post-PV); Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Interventions: Momelotinib; Best Available Therapy (BAT)
- Enrollment: 156
- Primary outcome: Splenic Response Rate at Week 24

## Commentary we found

- YouTube: 22
- Podcasts: 13
- X threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=simplify-2-nct02101268

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02101268", "email": "<work email>"}; the inbox owner confirms by the emailed link.